Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04171765 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT04171765 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 46 participants.
The verdict
NCT04171765, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).
Interventions
- DRUG Placebo
- DRUG BFKB8488A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2023-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04171765
The ClinicalTrials.gov registry entry for NCT04171765 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04171765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04171765 about?
NCT04171765 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis". This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).
What is the current status of trial NCT04171765?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2020-09-30. Estimated completion is 2023-01-23.
What interventions are being tested in trial NCT04171765?
The interventions under investigation include: Placebo (DRUG), BFKB8488A (DRUG).
Who is sponsoring clinical trial NCT04171765?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.